Possible scenario
Platform Expansion
20% Chance
The partnership expands beyond melanoma into additional tumor types where individualized neoantigen vaccines could be tested or commercialized. Tempus benefits from a broader role in trial matching, genomic profiling, and real-world evidence generation.
Secondary impacts
- Healthcare +0.6%
- Technology +0.3%
Tickers
- TEM+7.0%
- MRNA+3.1%
- PSNL+1.5%
- MRK+1.0%
Portfolio impact
S&P 500+0.2%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.